CWP
NMTR

Concord Wealth Partners’s 9 Meters Biopharma NMTR Stock Holding History

Concord Wealth Partners’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$1K – 1064
2021
Q2 		$1K Sell
50
-50
-50% -$1.23K ﹤0.01% 1022
2021
Q1 		$2K Buy
+100
New +$3.07K ﹤0.01% 866

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Concord Wealth Partners's NMTR Position: Q3 2021 in Review

Concord Wealth Partners sold out of 9 Meters Biopharma (NMTR) in Q3 2021, closing a stake of 50 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in NMTR in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q1 2021. 105 funds tracked by Wall St. Rank hold NMTR as of Q3 2021.

  • Concord Wealth Partners reported no remaining 9 Meters Biopharma position as of Q3 2021 after selling out during the quarter.
  • Concord Wealth Partners sold 50 9 Meters Biopharma shares in Q3 2021, an estimated $1K.
  • Concord Wealth Partners first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 2 quarters.
  • Concord Wealth Partners's 9 Meters Biopharma position peaked at $2K in Q1 2021.
  • 105 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2021.

Based on Concord Wealth Partners's 13F filing for Q3 2021, filed 9 Nov 2021.